🧬 Weekly report: p53 mutations & anti-cancer therapy response Highlight: broad reactivation of mutant p53 using DARPins biomed.news/bims-p53act/... @biomednews.bsky.social #p53 #Oncology #PrecisionMedicine

Mutant p53 & therapy response weekly report 🧬 Highlight: Low-penetrance TP53 variants are mainly hypomorphic Not all TP53 mutations are equal, some retain partial function with real clinical impact. @biomednews.bsky.social biomed.news/bims-p53act/... #p53 #CancerResearch

🧬 Mutant p53 & therapy response - Weekly report 🔬 Highlight: Covalent agonists targeting p53 Y220C restore its function and suppress tumor growth - real progress toward drugging mutant p53. 👉 biomed.news/bims-p53act/... @biomednews.bsky.social #p53 #Oncology

Mutant p53 & therapy response - weekly report 🧬 🔬 Highlight: TP53 mutations may predict poor response to taxane chemotherapy TP53 status isn’t just biology, it’s clinical. @biomednews.bsky.social #p53 #CancerResearch #Oncology biomed.news/bims-p53act/...

🧬 New report: Mutant p53 & cancer therapy - TP53 CpG site mutations define an immune-activated tumor subtype and predict improved response to first-line chemoimmunotherapy in lung adenocarcinoma. @biomednews.bsky.social #p53 #CancerResearch #Immunotherapy biomed.news/bims-p53act/...

🧬 New report: Mutant p53 & anti-cancer therapy response Highlights: - TP53 loss links mTOR activation and immune-cold MSS colorectal cancer - TP53 mutations associate with improved PFS with cetuximab+pembrolizumab in CRC @biomednews.bsky.social #p53 #CancerResearch biomed.news/bims-p53act/...

🧬 New Mutant p53 research report! Highlight: - TP53-mut diffuse follicular lymphoma with cnLOH at 1p36 highlights molecular profiling. - Mut p53 rewires CXCL10, boosting CD8⁺ T cells and anti-PD-1 response. @biomednews.bsky.social biomed.news/bims-p53act/... #p53 #CancerResearch

New Mutant p53 & Cancer Therapy Response Report is out! 🧬 Highlights: • Lung-specific p53 mutants bind DNA but fail to transactivate • Rezatapopt shows Phase I activity in Y220C tumors @biomednews.bsky.social #p53 #CancerResearch #Oncology biomed.news/bims-p53act/...

New weekly Mutant p53 & Anti-Cancer Therapy Response report out now 🧬🧠 This issue highlights: - Novel drug and prodrug candidates targeting TP53 mutations - TP53-dependent cell fate in glioblastoma @biomednews.bsky.social biomed.news/bims-p53act/... #p53 #Oncology #CancerResearch

New week, new report 🧬 My weekly Mutant p53 & anti-cancer therapy response report is out. Fresh evidence on how TP53 mutations shape treatment response in cancer. @biomednews.bsky.social #p53 #Cancer #Oncology #CancerTherapy #BiomedsNews biomed.news/bims-p53act/...

A new Biomeds News report is out 🚀 This week’s update on mutant p53 & anti-cancer therapy response - key papers, one place. @biomednews.bsky.social #p53 #CancerResearch #Oncology #BiomedsNews biomed.news/bims-p53act/...

Nou article a #Docusalut: Hotspot mutant p53-R273H enhances mitochondrial biogenesis and cell migration in primary colorectal cancer in response to oxaliplatin  http://hdl.handle.net/20.500.13003/26209  @idisba.bsky.social  #PublicaSalutIB

Here we go again! Kicking off 2026 🚀, my weekly report about mutant p53 and anti-cancer therapy response is out. @biomednews.bsky.social #p53 #Oncology #CancerTherapy #BiomedsNews biomed.news/bims-p53act/...

Just before Christmas🎄, my weekly Biomeds News report is out. Growing evidence shows the clinical relevance of mutant p53 in treatment response, positioning it as a key axis in anticancer therapy. @biomednews.bsky.social #p53 #Oncology biomed.news/bims-p53act/... Merry Christmas!!!

🧬Mutant p53 & anticancer therapy - weekly update. A curated snapshot of recent studies on therapy response, resistance and tumour adaptation across cancers. biomed.news/bims-p53act/... @biomednews.bsky.social #p53 #Oncology #CancerResearch

🧬 Our latest @biomednews.bsky.social report on mutant #p53 and anticancer therapy is out. Across multiple #Cancer types, recent studies highlight how TP53 #mutations intersect with tumor plasticity, DNA repair pathways, immune context and treatment response. biomed.news/bims-p53act/... #Oncology

Our new Biomed News issue on Mutant p53 & Anticancer Therapy is live - 9 fresh papers this week, spanning mechanisms, resistance, and new therapeutic angles. Great selection for anyone following the p53 field!🔬 biomed.news/bims-p53act/... @biomednews.bsky.social #p53 #CancerResearch #Oncology

🧬 New #BiomedNews report out in Mutant #p53 and anti-cancer therapies. Two recent papers highlight how specific TP53 mutations drive tumor behavior and reveal new therapeutic vulnerabilities. biomed.news/bims-p53act/... @biomednews.bsky.social

Take a look at our new report from @tonimarber.bsky.social

Toni Martinez@tonimarber.bsky.social · 10mo ago

I’m excited to launch my first @biomednews.bsky.social report: p53 mutations and anti-cancer therapy response 🧬 Starting small with 2 papers, more coming as ernad learns! 🚀 Exploring how mutant #p53 drives therapy adaptation. biomed.news/bims-p53act/... (And yes, my own recent paper’s included 👀)

I’m excited to launch my first @biomednews.bsky.social report: p53 mutations and anti-cancer therapy response 🧬 Starting small with 2 papers, more coming as ernad learns! 🚀 Exploring how mutant #p53 drives therapy adaptation. biomed.news/bims-p53act/... (And yes, my own recent paper’s included 👀)

Thrilled to share that the main paper from my PhD thesis is finally out!🧬 Our study shows how mutant p53 boosts mitochondrial biogenesis and cell migration under chemotherapy stress. www.sciencedirect.com/science/arti... @gmot16.bsky.social @uib.cat @iunics-uib.bsky.social @idisba.bsky.social

Hotspot mutant p53-R273H enhances mitochondrial biogenesis and cell migration in primary colorectal cancer in response to oxaliplatin

Oxaliplatin is commonly known as a successful chemotherapy for advanced colorectal cancer, improving patient survival and eradicating micro-metastases…

sciencedirect.com

Torn del Dr. Toni Martínez @tonimarber.bsky.social per explicar la seva tesi doctoral realitzada al grup @gmot16.bsky.social

Avui acabam el curs acadèmic 2024-25, i volem compartir algunes de les fites més destacades del grup de recerca GMOT aquest any. Comencem!👇

Per altra banda, el Dr. Toni Martínez @tonimarber.bsky.social, sota la direcció dels Drs. J. Oliver i J. Sastre, va centrar-se en l’estudi d’una mutació freqüent de la proteïna p53 i com pot impactar en la progressió del càncer colorectal. Enhorabona i bona sort amb el que t’espera a partir d’ara!🎉🔬

📣 Save the date! 23/06, 10:00h, sala grados B, ed. Jovellanos, UIB. @tonimarber.bsky.social defiende su tesis doctoral "Implicaciones de la mutación p53-R273H en la respuesta al oxaliplatino, la función mitocondrial y la señalización inflamatoria en el cáncer colorrectal". Don't miss it!🧫

🔥 Tu cuerpo no es un bosque, pero puede arder por dentro. El cáncer es el fuego. ¿Y si te digo que la obesidad es el viento que lo aviva? Tu cuerpo no es una metáfora… ¡Pero este #HiloTesis sí que lo es! 🌲🔥 @crueuniversidades.bsky.social @filarramendi.bsky.social @culturacientifica.uib.cat

the sun shines brightly through the clouds over a forest fire

ALT: the sun shines brightly through the clouds over a forest fire

media.tenor.com

Nou article a #Docusalut: Oxidative Phosphorylation as a Predictive Biomarker of Oxaliplatin Response in Colorectal Cancer http://hdl.handle.net/20.500.13003/21486 @idisba.bsky.social  #PublicaSalutIB

Kicking off my profile with some exciting news! 🎉 Part of my PhD thesis is now published: "Oxidative Phosphorylation as a Predictive Biomarker of Oxaliplatin Response in Colorectal Cancer" 🔬 Big thanks to the amazing GMOT team🙌 www.mdpi.com/3012746

Oxidative Phosphorylation as a Predictive Biomarker of Oxaliplatin Response in Colorectal Cancer

Oxaliplatin is successfully used on advanced colorectal cancer to eradicate micro-metastasis, whereas its benefits in the early stages of colorectal cancer remains controversial since approximately 30...

mdpi.com